Loading...
•
Mar 31, 2021
Checkpoint Therapeutics Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
Checkpoint Therapeutics reported its Q1 2021 financial results, highlighting the advancement of its lead drug candidates and an enhanced cash position. Enrollment in the registration-enabling study for cosibelimab in mCSCC is nearly complete, with top-line results expected by year-end. Neupharma Inc. is continuing enrollment in a Phase 3 study for olafertinib (CK-101) in NSCLC.
Advanced the development of two lead drug candidates.
Enhanced cash position.
Enrollment in registration-enabling study for cosibelimab in mCSCC is nearly complete.
Study remains on track to report top-line results by year-end.
Checkpoint Therapeutics
Checkpoint Therapeutics
Forward Guidance
The company anticipates submitting its first application for marketing approval for cosibelimab next year.